Cipla: $500m North American Sales Boost Possible In Five Years
Going Beyond Respiratory Key As Cipla Discloses Injectables Ambitions
Cipla’s recent US approval with a partner for its 505(b)(2) hybrid lanreotide injection product signaled the firm’s intentions to broaden in the peptides and injectables space, as it looks to add hundreds of millions to its revenue base by Cipla’s 2027 financial year.
